Ikarian Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ikarian Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,500	Closed	-$36.5M	–	148
2024 Q2	$36.5M	Sell	1,500 -135,200	-99%	-$21.3M	6.35%	2
2024 Q1	$20.4M	Buy	136,700 +38,100	+39%	+$6.36M	2.24%	10
2023 Q4	$18.9M	Buy	+98,600	New	+$16.8M	1.77%	18
2022 Q3	–	Sell	-39,900	Closed	-$5.82M	–	107
2022 Q2	$5.82M	Sell	39,900 -77,900	-66%	-$11.1M	1.06%	30
2022 Q1	$19.2M	Buy	+117,800	New	+$17.9M	2.53%	10
2021 Q3	–	Sell	-300,000	Closed	-$50.9M	–	218
2021 Q2	$50.9M	Buy	+300,000	New	+$43.9M	4.11%	2
2021 Q1	–	Sell	-50,000	Closed	-$6.5M	–	295
2020 Q4	$6.5M	Hold	50,000	–	–	0.29%	79
2020 Q3	$7.28M	Buy	+50,000	New	+$7.11M	0.53%	45
2020 Q2	–	Sell	-120,300	Closed	-$13.1M	–	170
2020 Q1	$13.1M	Buy	+120,300	New	+$13.9M	0.98%	26

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ikarian Capital's ALNY Position: Q3 2025 in Review

Ikarian Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 56,594 shares — an estimated $18.5M sold.

Ikarian Capital first reported a position in ALNY in Q3 2021 and held it in 9 quarters. The position peaked at $18.5M in Q2 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

Ikarian Capital reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Ikarian Capital sold 56,594 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $18.5M.
Ikarian Capital first reported a position in Alnylam Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Ikarian Capital's Alnylam Pharmaceuticals position peaked at $18.5M in Q2 2025.
821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.